Coreline Soft, a medical AI company, has begun to generate results by strengthening its solution supply contracts and partnerships with leading European hospitals.

Coreline Soft said Thursday that it has signed a contract to supply its flagship product, AVIEW LCS Plus, a simultaneous diagnosis solution for chest diseases, to the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland.

CHUV is a top-tier hospital ranked 13th in the world by U.S. Newsweek's World's Best Hospitals 2024. Coreline Soft said it was selected as the final solution provider after a 10-month competitive tender and met all of the performance evaluations conducted by CHUV, including customer service levels, sensitivity, and specificity criteria.

The company is also expanding its lung cancer research with major French hospitals. First, it introduced AVIEW LCS Plus to AP-HP Bichat Hospital to study patients with interstitial lung disease. AP-HP Bichat Hospital is one of the 38 hospitals of the AP-HP, the largest university public hospital organization in France, and an affiliated hospital of the University of Paris.

Coreline Soft has also completed the installation of AVIEW LCS Plus at FOCH Hospital for a research project on lung cancer diagnostics. The project aims to achieve global standards in chest disease diagnostics. FOCH is the largest public hospital in Paris and is recognized as a European and global authority in pulmonary, renal, urological, and neurological sciences.

In addition, Coreline Soft has successfully entered Spain. Hospital del Mar uses AVIEW LCS Plus for lung cancer data collection and clinical research analysis in Spain. Hospital del Mar is a general hospital in Barcelona and is part of the European Lung Cancer Screening Project (4ITLR), in which Coreline Soft is also involved.

According to the company, Europe requires specialized marketing, as each country's situation and medical regulations differ. Coreline Soft's strategy has been to take a long-term view, establishing a network of projects in the European Union, major countries, and regions and then identifying opportunities for cooperation. The company added that its early market penetration and trust building are starting to show tangible results, which will ripple effect across Europe, the neighboring Middle East, and Africa.

"We continue to prove our strength as a product and business partner through competitive bids and business collaborations with world-renowned hospitals," said Seo Jung-hyeok, director of Coreline Soft's Overseas Business Division. "With the references we have built, we will aggressively pursue high-potential and lucrative healthcare business opportunities across Europe."

Coreline Soft is expanding its footprint across Europe with a presence in the U.K., Germany, and Italy. The company plans to solidify its leadership position in the European healthcare AI market by exploring collaboration opportunities with local hospitals.

The European medical device market is the second largest in the world after North America, with an estimated value of 150 billion euros in 2021 (about 210 trillion won) and the world's largest per capita medical device market.